Stock NAUT NAUTILUS BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nautilus Biotechnology, Inc.

Equities

NAUT

US63909J1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 01/05/2024 am IST 		5-day change 1st Jan Change
2.54 USD -1.17% Intraday chart for Nautilus Biotechnology, Inc. +2.01% -15.05%
30/04 Transcript : Nautilus Biotechnology, Inc., Q1 2024 Earnings Call, Apr 30, 2024
30/04 Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Number of employees: 167

Managers

Managers TitleAgeSince
Parag Mallick FOU
 Founder 47 01/16/01
Sujal Patel FOU
 Founder 49 01/16/01
Anna Mowry DFI
 Director of Finance/CFO 46 09/21/09
Mary Godwin COO
 Chief Operating Officer 65 01/20/01
Chris Blessington IRO
 Public Communications Contact - 01/21/01
Nick Nelson PRN
 Corporate Officer/Principal 41 09/21/09
Martin Huber PRN
 Corporate Officer/Principal - 01/11
Subra Sankar PRN
 Corporate Officer/Principal 64 01/20/01
Matthew Murphy LAW
 General Counsel 59 09/21/09
Gwen Weld HRO
 Human Resources Officer 66 12/22/12

Members of the board

Members of the board TitleAgeSince
Matthew Posard CHM
 Chairman 56 01/19/01
Farzad Nazem BRD
 Director/Board Member 62 09/21/09
Matt McIlwain BRD
 Director/Board Member 59 09/21/09
Sujal Patel FOU
 Founder 49 01/16/01
Michael Altman BRD
 Director/Board Member 42 09/21/09
Melissa Epperly BRD
 Director/Board Member 46 09/21/09
Vijay Pande BRD
 Director/Board Member 53 09/21/09
Parag Mallick FOU
 Founder 47 01/16/01
Karen Akinsanya BRD
 Director/Board Member 56 30/22/30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 125,265,015 70,376,277 ( 56.18 %) 0 56.18 %

Shareholders

NameEquities%Valuation
Parag Mallick
16.53 %
20,679,892 16.53 % 61 M $
AH Capital Management LLC
14.11 %
17,653,917 14.11 % 52 M $
Sujal Patel
13.72 %
17,158,999 13.72 % 50 M $
Perceptive Advisors LLC
10.07 %
12,594,211 10.07 % 37 M $
Cercano Management LLC
5.734 %
7,172,985 5.734 % 21 M $
Madrona Venture Group LLC
4.813 %
6,020,770 4.813 % 18 M $
BlackRock Advisors LLC
2.927 %
3,661,489 2.927 % 11 M $
Vanguard Fiduciary Trust Co.
2.262 %
2,829,798 2.262 % 8 M $
Comprehensive Financial Management LLC (California)
1.765 %
2,207,619 1.765 % 6 M $
Bain Capital Life Sciences LP
1.599 %
2,000,000 1.599 % 6 M $

Company contact information

Nautilus Biotechnology, Inc.

2701 Eastlake Avenue East

98102, Seattle

+

http://www.nautilus.bio
address Nautilus Biotechnology, Inc.(NAUT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.54 USD
Average target price
4.25 USD
Spread / Average Target
+67.32%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NAUTILUS BIOTECHNOLOGY, INC. Stock Nautilus Biotechnology, Inc.
-15.05% 318M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.24B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NAUT Stock
  4. Company Nautilus Biotechnology, Inc.